MX2023014381A - Inhibidores de elemento nuclear largo intercalado 1 (line-1) como mejoradores cognitivos. - Google Patents
Inhibidores de elemento nuclear largo intercalado 1 (line-1) como mejoradores cognitivos.Info
- Publication number
- MX2023014381A MX2023014381A MX2023014381A MX2023014381A MX2023014381A MX 2023014381 A MX2023014381 A MX 2023014381A MX 2023014381 A MX2023014381 A MX 2023014381A MX 2023014381 A MX2023014381 A MX 2023014381A MX 2023014381 A MX2023014381 A MX 2023014381A
- Authority
- MX
- Mexico
- Prior art keywords
- line
- intercalated
- inhibitors
- long
- nuclear element
- Prior art date
Links
- 230000001149 cognitive effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 abstract 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 abstract 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 abstract 2
- 230000019771 cognition Effects 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 230000006999 cognitive decline Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163197015P | 2021-06-04 | 2021-06-04 | |
| PCT/US2022/032120 WO2022256625A1 (en) | 2021-06-04 | 2022-06-03 | Line-1 inhibitors as cognitive enhancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014381A true MX2023014381A (es) | 2023-12-15 |
Family
ID=84323626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014381A MX2023014381A (es) | 2021-06-04 | 2022-06-03 | Inhibidores de elemento nuclear largo intercalado 1 (line-1) como mejoradores cognitivos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240285664A1 (enExample) |
| EP (1) | EP4346835A4 (enExample) |
| JP (1) | JP2024520132A (enExample) |
| KR (1) | KR20240017910A (enExample) |
| CN (1) | CN117813096A (enExample) |
| AU (1) | AU2022283915A1 (enExample) |
| CA (1) | CA3221190A1 (enExample) |
| IL (1) | IL309036A (enExample) |
| MX (1) | MX2023014381A (enExample) |
| WO (1) | WO2022256625A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4358968A4 (en) * | 2021-06-22 | 2025-05-07 | Rome Therapeutics, Inc. | 4-ETHINYL-3-HYDROXY-TETRAHYDROFURANYL ADENINE PHOSPHORAMIDATE AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISEASES |
| EP4482498A4 (en) * | 2022-02-22 | 2026-02-25 | Rome Therapeutics Inc | METHODS OF TREATING MEDICAL PROBLEMS USING CENSAVUDINE OR A COMBINATION COMPOUND |
| US20250186475A1 (en) * | 2022-03-15 | 2025-06-12 | Rome Therapeutics, Inc. | Methods of treating medical conditions using islatravir or a related compound |
| WO2024107850A1 (en) * | 2022-11-15 | 2024-05-23 | Rome Therapeutics, Inc. | Halo-dehydro-3'-deoxyuracil phosphoramidates and related compounds and their use in treating medical conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0104168D0 (en) * | 2001-02-20 | 2001-04-11 | European Molecular Biology Lab Embl | Disease model |
| CA2986891C (en) * | 2015-05-26 | 2022-01-04 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Compositions for use in treating parkinson's disease and related disorders |
| MX2021008751A (es) * | 2019-01-25 | 2021-11-12 | Univ Brown | Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad. |
| US20220160710A1 (en) * | 2019-03-08 | 2022-05-26 | University Of Virginia Patent Foundation | Compositions and methods for treating or preventing alzheimer's disease |
| IL301564A (en) * | 2020-09-23 | 2023-05-01 | Transposon Therapeutics Inc | LINE-1 inhibitors to treat the disease |
-
2022
- 2022-06-03 AU AU2022283915A patent/AU2022283915A1/en active Pending
- 2022-06-03 KR KR1020247000214A patent/KR20240017910A/ko active Pending
- 2022-06-03 MX MX2023014381A patent/MX2023014381A/es unknown
- 2022-06-03 IL IL309036A patent/IL309036A/en unknown
- 2022-06-03 US US18/566,413 patent/US20240285664A1/en active Pending
- 2022-06-03 CN CN202280048917.1A patent/CN117813096A/zh active Pending
- 2022-06-03 CA CA3221190A patent/CA3221190A1/en active Pending
- 2022-06-03 EP EP22816917.3A patent/EP4346835A4/en active Pending
- 2022-06-03 JP JP2023574354A patent/JP2024520132A/ja active Pending
- 2022-06-03 WO PCT/US2022/032120 patent/WO2022256625A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240017910A (ko) | 2024-02-08 |
| EP4346835A4 (en) | 2025-04-16 |
| JP2024520132A (ja) | 2024-05-21 |
| US20240285664A1 (en) | 2024-08-29 |
| AU2022283915A1 (en) | 2024-01-18 |
| CA3221190A1 (en) | 2022-12-08 |
| WO2022256625A1 (en) | 2022-12-08 |
| IL309036A (en) | 2024-02-01 |
| CN117813096A (zh) | 2024-04-02 |
| EP4346835A1 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21080535A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| CL2020001752A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa. | |
| MX2019004616A (es) | Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina. | |
| CL2023000289A1 (es) | Combinaciones para el tratamiento de cáncer | |
| CO2020004034A2 (es) | Métodos para el tratamiento de distrofia muscular | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| CL2023000943A1 (es) | Formas cristalinas de un compuesto farmacéutico. | |
| CO2021007613A2 (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa | |
| CO2024000880A2 (es) | Compuestos para el tratamiento del dolor, en particular el dolor neuropático, y/u otras enfermedades o trastornos que se asocian con at2r y/o señalización mediada por at2r | |
| AR124078A1 (es) | Método para el tratamiento de la enfermedad de parkinson | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| CL2023003363A1 (es) | Composiciones y métodos para inhibir la expresión del componente reductor 1 de amidoxima de mitocondria (marc1) | |
| MX2023012851A (es) | Métodos de tratamiento y seguimiento de la enfermedad de parkinson. | |
| CO2023013442A2 (es) | Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos | |
| CL2023000857A1 (es) | Inhibidores line-1 para tratar la enfermedad | |
| CL2019002025A1 (es) | Derivados de pirrolotriazina como inhibidor de cinasas. | |
| CO2023017186A2 (es) | Formas cristalinas de trofinetida | |
| MX2023011720A (es) | Una composicion para su uso en el tratamiento de mhc-i-opatias. | |
| CO2025012293A2 (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| MX2024015839A (es) | Composiciones y usos de psilocibina y psilocina | |
| CO2024004737A2 (es) | Composiciones y métodos para el tratamiento de trastornos relacionados con pcdh19 | |
| MX2024008375A (es) | Metodos y composiciones para el tratamiento de la enfermedad de parkinson. | |
| CL2025000462A1 (es) | Composición farmacéutica para prevenir o tratar la nefritis | |
| ECSP24032618A (es) | Composiciones y métodos para el tratamiento de trastornos relacionados con pcdh19 | |
| MX2025013233A (es) | Formas polimorficas y formulaciones de leriglitazona |